Skip to content
naulon
Not checkedNot checked for notices yet.

Modeling SARS-CoV-2 infection and its individual differences with ACE2-expressing human iPS cells

Emi Sano, Sayaka Deguchi, Ayaka Sakamoto and 6 more

iScience · 2021

doi:10.1016/j.isci.2021.102428 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Summary: Genetic differences are a primary reason for differences in the susceptibility and severity of COVID-19. As induced pluripotent stem (iPS) cells maintain the genetic information of the donor, they can be used to model individual differences in SARS-CoV-2 infection in vitro. We found that human iPS cells expressing the SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) (ACE2-iPS cells) can be infected w SARS-CoV-2. In infected ACE2-iPS cells, the expression of SARS-CoV-2 nucleocapsid protein, budding of viral particles, and production of progeny virus, double membrane spherules, and double-membrane vesicles were confirmed. We performed SARS-CoV-2 infection experiments on ACE2-iPS/ embryonic stem (ES) cells from eight individuals. Male iPS/ES cells were more capable of producing the virus compared with female iPS/ES cells. These findings suggest that ACE2-iPS cells can not only reproduce individual differences in SARS-CoV-2 infection in vitro but also are a useful resource to clarify the causes of individual differences in COVID-19 due to genetic differences.

Abstract licence: CC BY-NC

References37

  1. 1.
  2. 5.
  3. 7.
  4. 10.
  5. 13.
  6. 14.
  7. 15.
  8. 18.
  9. 19.
  10. 25.
  11. 29.
  12. 30.
  13. 33.
  14. 34.

23 more references, whose wording the paper’s licence keeps private.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.